CVS Health Corporation filed a Form 8-K on August 17, 2026, reporting the resignation of director Larry M. Robbins and the appointment of Teresa Heitsenrether to the Board of Directors, effective November 18, 2026.

Key Highlights

  • Resignation: Larry M. Robbins notified the Board of his resignation, effective immediately on August 13, 2026.
  • No disagreement: According to the filing, Mr. Robbins' resignation "was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company."
  • New director appointed: Teresa Heitsenrether was appointed to the Board on August 17, 2026, with her service commencing November 18, 2026.
  • Current role: Ms. Heitsenrether, age 61, is Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase & Co. and a member of JPMorgan's Operating Committee.
  • Independence determination: The CVS Health Board determined Ms. Heitsenrether to be "independent" under New York Stock Exchange Corporate Governance Rules and the Company's Corporate Governance Guidelines.
  • Compensation: Ms. Heitsenrether's director compensation will be consistent with other non-employee directors, prorated to reflect her commencement date.

Board Composition Shift at CVS Health in August 2026

CVS Health Corporation (NYSE:CVS), headquartered in Woonsocket, Rhode Island, disclosed two simultaneous changes to its Board of Directors in this filing. On August 13, 2026, Larry M. Robbins notified the Board of his resignation, which took effect immediately. The filing states his departure was not connected to any disagreement with the company regarding its operations, policies, or practices.

The Board responded on August 17, 2026, by appointing Teresa Heitsenrether as a new director, with her service set to begin on November 18, 2026. According to the filing, Ms. Heitsenrether currently serves as Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase & Co. and sits on JPMorgan's Operating Committee. Her prior roles at JPMorgan Chase included CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing. She holds an M.B.A. from New York University and a B.S. in Finance from Fordham University.

The filing notes that there were no arrangements or understandings pursuant to which Ms. Heitsenrether was appointed, and that since the beginning of the last fiscal year, no related party transactions between the company and Ms. Heitsenrether would be reportable under Item 404(a) of Regulation S-K. Her compensation as a non-employee director will follow the practices described in the company's annual proxy statement filed with the SEC on April 3, 2026, subject to proration based on her start date.

What Was Disclosed

CVS Health disclosed the immediate resignation of board member Larry M. Robbins on August 13, 2026, and the appointment of Teresa Heitsenrether, a JPMorgan Chase executive, to the Board effective November 18, 2026, including her independence determination and compensation terms.